Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ownership Breakdown Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Top institutional share ownership of Ultragenyx Pharmaceutical Inc

Name Shares Shares % change Value Value % change
Vanguard Group Inc 6,161,866 0.5% $255,163 -30.3%
Wellington Management Group Llp 6,046,038 37.0% $250,367 -4.9%
Price T Rowe Associates Inc /md/ 4,756,956 -55.9% $196,987 -69.4%
BlackRock Inc. 3,927,639 9.2% $162,645 -24.2%
Federated Hermes, Inc. 3,816,397 0.5% $158,037 -30.2%
Capital International Investors 3,391,082 -0.6% $140,425 -31.0%
Clearbridge Investments, LLC 2,762,822 -2.6% $114,408 -32.4%
T. Rowe Price Investment Management, Inc. 2,607,431 $107,974
State Street Corp 2,559,544 4.2% $105,991 -27.7%
Rtw Investments, Lp 2,359,996 71.9% $97,727 19.3%

Top institutional buyers of Ultragenyx Pharmaceutical Inc

Name Shares % change Value % change Shares Value
Rtw Investments, Lp 71.9% 19.3% 2,359,996 $97,727
Avidity Partners Management LP 38.7% -3.8% 2,051,600 $84,957
Wellington Management Group Llp 37.0% -4.9% 6,046,038 $250,367
HFMCX - THE HARTFORD MIDCAP FUND Class A 27.0% -4.2% 1,636,507 $87,193
VEXPX - VANGUARD EXPLORER FUND Investor Shares 25.5% -5.4% 1,491,686 $79,477
BlackRock Inc. 9.2% -24.2% 3,927,639 $162,645
Rock Springs Capital Management LP 8.7% -24.6% 1,187,992 $49,195
XBI - SPDR(R) S&P(R) Biotech ETF 6.7% -26.0% 1,542,391 $63,870
Alliancebernstein L.p. 6.4% -26.1% 1,313,533 $54,393
State Street Corp 4.2% -27.7% 2,559,544 $105,991

Top institutional sellers of Ultragenyx Pharmaceutical Inc

Name Shares % change Value % change Shares Value
Price T Rowe Associates Inc /md/ -55.9% -69.4% 4,756,956 $196,987
PRNHX - T. Rowe Price New Horizons Fund, Inc. -28.9% -50.6% 1,507,304 $62,417
PRHSX - T. Rowe Price Health Sciences Fund, Inc. -24.2% -47.4% 1,179,514 $48,844
Alkeon Capital Management Llc -10.4% -37.8% 2,211,959 $91,597
ANWPX - NEW PERSPECTIVE FUND Class A -10.0% -26.1% 1,230,897 $73,435
Clearbridge Investments, LLC -2.6% -32.4% 2,762,822 $114,408
KAUAX - Federated Kaufmann Fund Class A Shares -1.3% -25.6% 1,500,000 $79,920
Capital International Investors -0.6% -31.0% 3,391,082 $140,425

Information provided by Fintel.io